Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma Meeting Abstract
| Authors: | Raje, N.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Damore, M. A.; Jiang, S.; Basu, C.; Skoura, A.; Chan, E. M.; Trudel, S.; Jakubowiak, A.; Chu, M. P.; Gasparetto, C. J.; Dalovisio, A. P.; Sebag, M.; Lesokhin, A. M. |
| Abstract Title: | Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 388 |
| End Page: | 390 |
| Language: | English |
| ACCESSION: | WOS:000893223200159 |
| DOI: | 10.1182/blood-2022-166494 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
